Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hartmut Grasemann

Showing results (11-20 of 138) with videos related to

Pageof 14
Sort By:
Naunyn-Schmiedeberg'S Archives of Pharmacology|October 13, 2006
Disease modifying genes in cystic fibrosis: therapeutic option or one-way road?Rainer Büscher, Hartmut Grasemann
The Lancet. Respiratory Medicine|January 17, 2014
Early lung disease in cystic fibrosisHartmut Grasemann, Felix Ratjen
Journal of Leukocyte Biology|January 6, 2010
Editorial: leukocyte trafficking and matrix metalloproteinase-8 in obliterative bronchiolitisHartmut Grasemann, Felix Ratjen
Current Pharmaceutical Design|January 11, 2012
New therapies in cystic fibrosisFelix Ratjen, Hartmut Grasemann
Current Pharmaceutical Design|January 11, 2012
Nitric oxide and L-arginine deficiency in cystic fibrosisHartmut Grasemann, Felix Ratjen
American Journal of Respiratory and Critical Care Medicine|May 17, 2022
How Should the Effects of CFTR Modulator Therapy on Cystic Fibrosis Lung Disease Be Monitored?Elad Ben-Meir, Hartmut Grasemann
Chest|August 7, 2013
Asymmetric dimethylarginine: a disease marker for asthma?Jeremy A Scott, Hartmut Grasemann
Immunology and Allergy Clinics of North America|October 6, 2014
Arginine metabolism in asthmaJeremy A Scott, Hartmut Grasemann
The European Respiratory Journal|June 12, 2026
Precision medicine in the era of CFTR modulator therapy: what comes next?José Fontoura-Matias, Hartmut Grasemann
International Journal of Molecular Sciences|December 16, 2020
Potential of the Electronic Nose for the Detection of Respiratory Diseases with and without InfectionJohann-Christoph Licht, Hartmut Grasemann
Pageof 14

Showing results (11-20 of 138) with videos related to

Sort By:
Pageof 14
Naunyn-Schmiedeberg'S Archives of Pharmacology|October 13, 2006
Disease modifying genes in cystic fibrosis: therapeutic option or one-way road?Rainer Büscher, Hartmut Grasemann
The Lancet. Respiratory Medicine|January 17, 2014
Early lung disease in cystic fibrosisHartmut Grasemann, Felix Ratjen
Journal of Leukocyte Biology|January 6, 2010
Editorial: leukocyte trafficking and matrix metalloproteinase-8 in obliterative bronchiolitisHartmut Grasemann, Felix Ratjen
Current Pharmaceutical Design|January 11, 2012
New therapies in cystic fibrosisFelix Ratjen, Hartmut Grasemann
Current Pharmaceutical Design|January 11, 2012
Nitric oxide and L-arginine deficiency in cystic fibrosisHartmut Grasemann, Felix Ratjen
American Journal of Respiratory and Critical Care Medicine|May 17, 2022
How Should the Effects of CFTR Modulator Therapy on Cystic Fibrosis Lung Disease Be Monitored?Elad Ben-Meir, Hartmut Grasemann
Chest|August 7, 2013
Asymmetric dimethylarginine: a disease marker for asthma?Jeremy A Scott, Hartmut Grasemann
Immunology and Allergy Clinics of North America|October 6, 2014
Arginine metabolism in asthmaJeremy A Scott, Hartmut Grasemann
The European Respiratory Journal|June 12, 2026
Precision medicine in the era of CFTR modulator therapy: what comes next?José Fontoura-Matias, Hartmut Grasemann
International Journal of Molecular Sciences|December 16, 2020
Potential of the Electronic Nose for the Detection of Respiratory Diseases with and without InfectionJohann-Christoph Licht, Hartmut Grasemann
Pageof 14